Compare MNOV & GPMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNOV | GPMT |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | 28 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.4M | 75.2M |
| IPO Year | 2004 | N/A |
| Metric | MNOV | GPMT |
|---|---|---|
| Price | $1.42 | $1.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $7.50 | $3.00 |
| AVG Volume (30 Days) | 21.8K | ★ 119.7K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 12.99% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,360,807.00 | N/A |
| Revenue This Year | N/A | $458.85 |
| Revenue Next Year | $180.00 | $8.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 194.15 | N/A |
| 52 Week Low | $1.17 | $1.24 |
| 52 Week High | $1.96 | $3.12 |
| Indicator | MNOV | GPMT |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 50.65 |
| Support Level | $1.40 | $1.24 |
| Resistance Level | $1.43 | $1.66 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 37.71 | 54.01 |
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the commercial property.